Please use this identifier to cite or link to this item:
Title: Expression of insulin-Like growth factor binding protein-5 (IGFBP5) reverses cisplatin-Resistance in esophageal carcinoma
Authors: Chan, D 
Zhou, YY 
Chui, CH 
Lam, KH 
Law, S
Chan, ASC
Li, XS
Lam, AKY
Tang, JCO 
Keywords: Cisplatin resistance
Esophageal squamous cell carcinoma
Insulin-like growth factor binding protein-5
Issue Date: 2018
Publisher: Molecular Diversity Preservation International (MDPI)
Source: Cells, Oct. 2018, v. 7, no. 10, 143, p. 1-15 How to cite?
Journal: Cells 
Abstract: Cisplatin (CDDP) is one of the front-line chemotherapeutic drugs used in the treatment of esophageal squamous cell carcinoma (ESCC). Occurrence of resistance to CDDP has become one of the main challenges in cancer therapy. In this study, the gene expression profile of CDDP-resistant ESCC cells was investigated and molecular approaches were explored in an attempt to reverse the CDDP resistance. A CDDP-resistant SLMT-1/CDDP1R cell line was established from SLMT-1 cells by subculturing in the medium containing an increasing concentration of CDDP (0.1-1 mu g/mL). Mitochondrial (MTS) cytotoxicity assay, cell proliferation assay and cell morphology were used to assess the acquisition of cisplatin-resistance. The most differentially expressed gene in SLMT-1/CDDP1R cells was identified by cDNA microarray analysis compared with the parental SLMT-1 cells and validated by quantitative real-time polymerase chain reaction (qPCR). Association between expression of the most differentially expressed target gene to cisplatin-resistance was verified by RNA interference. An attempt to reversecisplatin-resistance phenotypes was made by using the vector expressing the most downregulated target gene in the CDDP-resistant cells. A CDDP-resistant ESCC cell line, SLMT-1 /CDDP1R, was established with 2.8-fold increase CDDP-resistance (MTS50 = 25.8 mu g/mL) compared with the parental SLMT-1 cells. cDNA microarray analysis revealed that IGFBP5 showed the highest level of downregulation in SLMT-1 /CDDP1R cells compared with the parental SLMT-1 cells. Suppression of IGFBP5 mediated by IGFBP5-targeting siRNA in parental SLMT-1 cells confirmed that IGFBP5 suppression in ESCC cells would induce CDDP-resistance. More importantly, upregulation of IGFBP5 using IGFBP5 expression vector reduced cisplatin-resistance in SLMT-1/CDDP1R cells by 41%. Thus, our results demonstrated that IGFBP5 suppression is one of the mechanisms for the acquisition of cisplatin-resistance in ESCC cells. Cisplatin-resistance phenotype can be reversed by increasing the expression level of IGFBP5. The overall findings of this study thus offered a new direction for reversing the CDDP resistance in ESCC and possibly in other cancer types with further investigations in future.
EISSN: 2073-4409
DOI: 10.3390/cells7100143
Rights: © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (
The following publication Chan, D., Zhou, Y.Y., Chui, C.H., Lam, K.H., Law, S., Chan, A.S.C., ... & Tang, J.C.O. (2018). Expression of insulin-Like growth factor binding protein-5 (IGFBP5) reverses cisplatin-Resistance in esophageal carcinoma. Cells, 7 (10), 143, p. 1-15 is available at
Appears in Collections:Journal/Magazine Article

Files in This Item:
File Description SizeFormat 
Chan_Insulin-like_Protein-5_Cisplatin-resistance.pdf1.71 MBAdobe PDFView/Open
View full-text via PolyU eLinks SFX Query
Show full item record
PIRA download icon_1.1View/Download Contents


Last Week
Last month
Citations as of Mar 19, 2019

Page view(s)

Citations as of Mar 22, 2019


Citations as of Mar 22, 2019

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.